171 results about "Ribosomal protein" patented technology

The present invention relates generally to compositions and methods for enhancing recombinational cloning of nucleic acid molecules. In particular, the invention relates to compositions comprising one or more ribosomal proteins and one or more additional protein components required for recombinational cloning. More particularly, the invention relates to such compositions wherein the ribosomal proteins are one or more E. coli ribosomal proteins, still more particularly wherein the ribosomal proteins are selected from the group of E. coli ribosomal proteins consisting of S10, S14, S15, S16, S17, S18, S19, S20, S21, L20, L21, and L23 through L34, and most particularly S20, L27, and S15. The invention also relates to the use of these compositions in methods for recombinational cloning of nucleic acids, in vitro and in vivo, to provide chimeric DNA molecules that have particular characteristics and/or DNA segments. The invention also relates to isolated nucleic acid molecules produced by the methods of the invention, to vectors comprising such nucleic acid molecules, and to host cells comprising such nucleic acid molecules and vectors.

The invention provides methods for isolating cell-type specific mRNAs by selectively isolating ribosomes or proteins that bind mRNA in a cell type specific manner, and, thereby, the mRNA bound to the ribosomes or proteins that bind mRNA. Ribosomes, which are riboprotein complexes, bind mRNA that is being actively translated in cells. According to the methods of the invention, cells are engineered to express a molecularly tagged ribosomal protein or protein that binds mRNA by introducing into the cell a nucleic acid comprising a nucleotide sequence encoding a ribosomal protein or protein that binds mRNA fused to a nucleotide sequence encoding a peptide tag. The tagged ribosome or mRNA binding protein can then be isolated, along with the mRNA bound to the tagged ribosome or mRNA binding protein, and the mRNA isolated and further used for gene expression analysis. The methods of the invention facilitate the analysis and quantification of gene expression in the selected cell type present within a heterogeneous cell mixture, without the need to isolate the cells of that cell type as a preliminary step.

The present invention provides live, attenuated Mycoplasma bacteria that exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal protein L35, relative to a wild-type Mycoplasma bacterium of the same species. Also provided are vaccines and vaccination methods involving the use of the live, attenuated Mycoplasma bacteria, and methods for making live attenuated Mycoplasma bacteria.

The present invention relates to novel methods for modulating the activity of p53 tumor suppressor protein by affecting p53 translational regulation. More specifically, the invention relates to novel methods for modulating p53 mRNA translation in a cell by affecting a function of a p53 5′-untranslated region (5′UTR), including its interaction with proteins such as Ribosomal Protein L26 (RPL26), nucleolin, and p53. The invention also relates to the use of these methods for treating cancer, neurodegenerative disorders and minimizing the negative effects of cellular stresses.

Belonging to the field of agricultural biotechnology, the invention relates to a laodelphax striatellus lethal gene fragment. By a laboratory improved dsRNA feeding method, the invention, from laodelphax striatellus, screens out the laodelphax striatellus lethal gene fragment Ribosomal protein L9-B which can lead to laodelphax striatellus death and has sequences as shown in SEQ ID No.1. Feeding laodelphax striatellus with the dsRNA of the gene fragment provided in the invention can have good lethal effect, thus providing sequence and data bases for establishing new strategies of pest control with RNA interference technology.

In this invention, a method is described that allows for the efficient creation and identification of validated biological materials that greatly enhance the ability to perform polysome-mediated RNA profiling, such as constitutive, cell type-, tissue type-, or condition-enhanced RNA profiling. The method relies on the use of a tri-partite plant binary expression vector comprised of the following components: a) a DNA promoter element that drives expression of a sequence specific transcription activator protein such as a LexA:Gal4 fusion protein in a unique desired pattern, b) a DNA promoter element comprising a target site for the transcriptional activator protein, such as opLexA, fused to a nucleotide encoding an epitope tagged ribosomal component protein and c) a DNA promoter element comprising a target site for the transcriptional activator protein, such as opLexA, fused to a nucleotide encoding an in vivo reporter protein. By visualization of the co-regulated reporter, this method allows for in planta confirmation that the promoter element is driving expression, such as constitutive, cell type-, tissue type-, or condition-enhanced expression, of the tagged ribosomal protein in the desired cell or tissue types.

The present invention provides recombinant DNA comprising a transcription promoter and a downstream sequence to be expressed, in operable linkage therewith, wherein the transcription promoter comprises a region found upstream of the open reading frame of a highly expressed Phaffia gene, preferably a glycolytic pathway gene, more preferably the gene coding for Glyceraldehyde-3-Phosphate Dehydrogenase. Further preferred recombinant DNAs according to the invention contain promoters of ribosomal protein encoding genes, more preferably wherein the transcription promoter comprises a region found upstream of the open reading frame encoding a protein as represented by one of the disclosed amino acid sequences. According to a further aspect of the invention an isolated DNA sequence coding for an enzyme involved in the carotenoid biosynthetic pathway of Phaffia rhodozyma is provided.

The invention discloses a molecular marker associated with colorectal carcinoma metastasis and prognosis as well as application of the molecular marker. The molecular marker is a ribosomal protein analog RPL22L1 (Ribosomal protein L22-like 1). A research proves that the ribosomal protein analog RPL22L1 is associated with occurrence and development of tumors, expression levels of the ribosomal protein analog in clinical colorectal carcinoma tissues rise, the expression levels of the ribosomal protein analog are obviously associated with metastasis occurrence and poor prognosis, and the colorectal carcinoma metastasis can be promoted by multiple regulation pathways. According to the molecular marker associated with colorectal carcinoma metastasis and prognosis disclosed by the invention, by detecting the expression levels of RPL22L1 genes in the colorectal carcinoma, the RPL22L1 as a tumor molecular diagnosis marker is applied to clinical diagnosis of the colorectal carcinoma metastasis and prognosis evaluation, so that a new molecular marker is provided for early diagnosis on the colorectal carcinoma metastasis and prognosis evaluation of colorectal carcinoma patients.

DNA sequences are identified that are useful in the diagnosis of gynaecological conditions such as endometriosis. Some of the sequences have a high identity with gene of known function such as Pim-2 oncogenes, IGFBP-5, ribosomal protein L41, propsaponin, fibulin-1, DLX5, 11β hydroxysteroid dehydrogenase type 2, SET, and RhoE. Methods for diagnosing or monitoring the progression of a gynaecological condition such as endometriosis may use primers directed to the DNA sequences identified herein.

The invention provides a screening method of a non-ribosomal protein-RNA composite near-nature structure, and belongs to the field of protein-RNA molecular docking composite structure prediction. Firstly, various possible combination modes of protein-RNA are obtained through conformation searching; then rationality of the combination modes is assessed, static and van and der waals interaction energy among the protein-RNA molecules and amino acid nucleotide pairing preference on composite interfaces are comprehensively taken into consideration, and the weight of each item is obtained in the mode that a linear regression method is adopted and accordingly fitting of a ligand root-mean-square deviation and weighted combination values of energy items of a docking structure is carried out; finally, according to the order that the values are sequenced from smaller ones to larger ones, a near-nature structure is judged. The screening method has a good effect on screening of the non-ribosomal protein-RNA molecular docking near-nature structure, the successful rate is high, and the method can be used for the field of protein-RNA composite structure prediction and provides an important basis for molecule improvement and design.

This invention relates to a balsam pear seed ribosome inactivating protein(RIP) and its encode gene and application. This protein has one of the undermentioned amino acid residue sequence: (1) SEQ ID NO:1 in the sequence table; (2) carry out substitution, deficiency or addition of protein that possess activity of inhibiting ribosomal protein synthesis to one to ten amino acid residue of SEQ ID NO: 1 amino acid residue sequence in sequence table. This protein possess hereinafter point: (1) notable effect of resisting tumour and virus infection; (2) high security; (3) simple protein expression condition, easy purification. low cost.

A method for producing a plant with increased yield as compared to a corresponding wild type plant whereby the method comprises at least the following step: increasing or generating in a plant or a part thereof one or more activities of a polypeptide selected from the group consisting of 26S proteasome-subunit, 50S ribosomal protein L36, Autophagy-related protein, B0050-protein, Branched-chain amino acid permease, Calmodulin, carbon storage regulator, FK506-binding protein, gamma-glutamyl-gamma-aminobutyrate hydrolase, GM02LC38418-protein, Heat stress transcription factor, Mannan polymerase II complex subunit, mitochondrial precursor of Lon protease homolog, MutS protein homolog, phosphate transporter subunit, Protein EFR3, pyruvate kinase, tellurite resistance protein, Xanthine permease, and YAR047C-protein.

The invention mainly relates to construction of a gene silencing vector induced by Chinese wheat yellow mosaic virus, and application thereof to nicotiana benthamiana. The biological active analysis results show that the constructed CWMV-VIGS can successfully infect the nicotiana benthamiana and can realize the silencing after the effective transcription on relevant genes such as phytoene desaturase and 50S ribosomal protein L12. The types of the VIGS vectors are enriched; in addition, the effective technical measures are provided for the gene function study.

The invention provides application of HPRT1 (hypoxanthine-guanine phosphoribosyltransferase 1), RPLP0 (ribosomal protein, large, P0) and HMBS (hydroxymethylbilane synthase) in the preparation as a reference gene in the preparation of kits or devices for studying or detecting polycystic ovarian syndrome. The invention also provides application of the HPRT1, RPLP0 and HMBS combination as kits or devices for studying or detecting hydroxymethylbilane synthase, such as real-time fluorescence quantitative PCR kits or gene chips.

The application discloses markers associated with organ transplant rejection and associated conditions, and in particular provides materials and methods for the diagnosis, prognosis or treatment of chronic rejection of transplanted organ such as heart and kidney. Examples of the markers include ribosomal protein L7, β-transducin, 1-TRAF (also known as TANK) or lysyl-tRNA synthetase, or antibodies against these antigens.

The invention provides a plant disease-resistant regulation and control gene. An open reading frame of the gene is 471 bp in length; and the gene encodes a ubiquitin extended protein consisting of 156 amino acids. The N end of the gene coded product is a ubiquitin molecule comprising 76 amino acids and the C end of the gene coded product is 40S ribosomal protein s27a comprising 80 amino acids. The gene is a high-quality disease-resistant gene resource. A disease-resistant material obtained by the gene has high resistance and a wide disease-resistant spectrum and can promote growth of plants. The gene widely joints in the regulation and control on resistance of various diseases caused by various pathogens by translating various kinds of targeted proteins and regulating modification after translation and joints in the regulation and control on growth and development of the plants. Due to overexpression of a tobacco UEP gene, the resistance of tobacco to various diseases such as Leptosphaeria maculans, wildfire, viral disease and the like is obviously improved. The plant disease-resistant regulation and control gene is applicable to creation and breeding of disease-resistant plant materials and varieties which have high resistance and wide disease-resistant objects and can promote growth of the plants.

The present invention provides a gene of ribosomal protein L7/L12 of strain M5 of brucellaovis as well as the encoding protein and the application of the gene. The encoding protein of the gene of the present invention has the amino acid sequence of SEQ ID NO.2. Gene vaccine can be prepared by utilizing the gene of the present invention; siRNA or shRNA or microRNA, which is designed and synthesized according to the sequence of the present invention, can be used for gene silencing. Developing a recombinant protein vaccine or exploring a detection kit can be realized by preparing the expressing protein of the gene of the present invention, thereby providing new effective solving ways to brucellosis.

To provide a method for discriminating a microorganism including: a step of subjecting a sample containing a microorganism to mass spectrometry to obtain a mass spectrum; a reading step of reading a mass-to-charge ratio m/z of a peak derived from a marker protein from the mass spectrum; and a discrimination step of discriminating which bacterial species of Escherichia coli, Shigella bacteria, and Escherichia albertii the microorganism contained in the sample contains based on the mass-to-charge ratio m/z, in which at least one of 13 ribosomal proteins S5, L15, S13, L31, L22, L19, L20, L13, S15, L25, HNS, HdeB, and L29 is used as the marker protein.

The present invention relates to the use of a peptide of P0 ribosomal protein in the manufacture of a vaccine composition to control of ectoparasite infestations and therefore the transmission of their associated pathogens. This peptide is located between 267 and 301 amino acids of the P0 protein, and can be obtained by recombinant means or by chemical synthesis. This peptide can be fused to a carrier protein or peptide, or an immuno-carrier and be included in an oily formulation. The formulations comprising the peptide vaccine confer protection against ticks and ectoparasites known as “sea lice” without generating autoimmunity in the host organism. Among these ticks may be mentioned species as Rhipicephalus microplus, Rhipicephalus sanguineus and Ixodes scapularis, and between sea lice are those of the Caligus and Lepeophtheirus genera.

The invention discloses an application of a human ribosomal protein L10 as a drug target for preventing and treating tumor related diseases. The amino acid sequence of the human ribosomal protein L10 is represented by the SEQ ID No.1. The human ribosomal protein L10 can be used as a drug target for in-vitro screening to prevent and treat tumor related diseases.

The invention discloses a polypeptide for inhibiting proliferation of tumor cells, which is of a fragment with maximum length of 145 amino acid residues at 46-100 position from N-terminal, comprising ribosomal protein RPL26. The reporter gene experiments, Western blotting, co-immunoprecipitation and cell proliferation detection experiments confirm that RPL26 as well as MDM2 and p53 form a complex, and the combination of RPL26 and MDM2 can obviously reduce the ubiquitin ligase activity of MDM2, thereby improving the stability and transcriptional activation of p53. The overexpression of RPL26 can obviously inhibit the proliferation of the tumor cells, and the function is related to the activity of p53. RPL26 can be assisted for the clinical treatment of cancer and has great significance.